Scarica l'app Stockscreener
126.20
0.05%
-0.06
Dopo l'orario di chiusura:
126.08
-0.12
-0.10%
Precedente Chiudi:
$126.26
Aprire:
$126.65
Volume 24 ore:
5.90M
Relative Volume:
3.55
Capitalizzazione di mercato:
$13.41B
Reddito:
$612.78M
Utile/perdita netta:
$-86.37M
Rapporto P/E:
-145.06
EPS:
-0.87
Flusso di cassa netto:
$-62.91M
1 W Prestazione:
+33.02%
1M Prestazione:
+45.12%
6M Prestazione:
+64.95%
1 anno Prestazione:
+91.36%
Intervallo 1D:
$126.16
$126.73
Intervallo di 1 settimana:
$126.00
$128.00
Portata 52W:
$62.78
$128.00
Intra Cellular Therapies Inc Stock (ITCI) Company Profile
Nome
Intra Cellular Therapies Inc
Settore
Telefono
(646) 440-9333
Indirizzo
135 ROUTE 202/206, BEDMINSTER, NY
Confronta ITCI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ITCI
Intra Cellular Therapies Inc
|
126.20 | 13.41B | 612.78M | -86.37M | -62.91M | -0.87 |
|
ZTS
Zoetis Inc
|
165.89 | 74.84B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
12.92 | 40.96B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.92 | 24.83B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
143.26 | 14.50B | 2.24B | 385.90M | 440.10M | 3.73 |
Intra Cellular Therapies Inc Stock (ITCI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-06 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-01-03 | Iniziato | Robert W. Baird | Outperform |
| 2023-12-11 | Iniziato | TD Cowen | Outperform |
| 2023-04-20 | Iniziato | Morgan Stanley | Overweight |
| 2022-08-22 | Downgrade | Goldman | Buy → Neutral |
| 2022-07-07 | Iniziato | Mizuho | Buy |
| 2022-06-14 | Iniziato | UBS | Buy |
| 2022-04-22 | Iniziato | Piper Sandler | Neutral |
| 2022-02-16 | Iniziato | Goldman | Buy |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2020-12-15 | Iniziato | BofA Securities | Buy |
| 2020-12-10 | Iniziato | Goldman | Buy |
| 2020-02-20 | Iniziato | Evercore ISI | Outperform |
| 2020-01-31 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-12-24 | Reiterato | Canaccord Genuity | Buy |
| 2019-08-12 | Iniziato | Jefferies | Buy |
| 2018-02-26 | Iniziato | JP Morgan | Overweight |
| 2018-02-08 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-12-15 | Iniziato | Canaccord Genuity | Buy |
| 2017-11-08 | Aggiornamento | SunTrust | Hold → Buy |
| 2017-09-07 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2017-08-30 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2017-08-24 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-08-23 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2017-05-02 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2017-05-02 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2017-05-01 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-12-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-09-29 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-09-29 | Downgrade | SunTrust | Buy → Neutral |
Mostra tutto
Intra Cellular Therapies Inc Borsa (ITCI) Ultime notizie
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LTRPA, OMIC, ITCI, CCNE on Behalf of Shareholders - Morningstar
3,043 Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Acquired by Avanza Fonder AB - MarketBeat
Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales - MSN
Why Intra-Cellular Therapies, Inc. (ITCI) Dominated Last Week’s Rally - Insider Monkey
MicroStrategy, SoFi Technologies And Carvana Are Among Top Large-Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio? - Benzinga
Oak Ridge Investments LLC Boosts Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Assenagon Asset Management S.A. Has $12.20 Million Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Jim Cramer on Intra-Cellular Therapies, Inc. (ITCI): ‘Intra-Cellular Had Something’ - Insider Monkey
Jim Cramer Recently Discussed These 15 Stocks & The California Wildfires - Insider Monkey
J&J to Acquire Intra-Cellular for About $14.6 Billion - MSN
Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer - MSN
Is Johnson & Johnson Stock Set to Reward Long-Term Holders? - Benzinga
Johnson & Johnson exploring takeover of Intra-CellularBloomberg - MSN
Intra-Cellular (ITCI) Surges 14.9%: Is This an Indication of Further Gains? - MSN
Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal - MSN
J&J explores bid for Intra-Cellular Therapies, Bloomberg News reports - MSN
Why Intra-Cellular (ITCI) Led the Monday Upsurge? - MSN
These Stocks Are Moving the Most Today: Micron, Intra-Cellular Therapies, and More - MSN
J&J to acquire psychiatric drugs maker Intra-Cellular for $14.6 billion - MSN
Intra-Cellular Therapies (NASDAQ:ITCI) Raised to “Strong-Buy” at Cantor Fitzgerald - Defense World
Johnson & Johnson Strikes $14.6 Billion Deal to Acquire Intra-Cellular Therapies - MSN
J&J buys Intra-Cellular in $14.6 billion deal, delving further into central nervous system disorders - MSN
J&J to buy Intra-Cellular for $132/share in cash - MSN
J&J doubles down on neurological drugs with $14.6 billion Intra-Cellular deal - MSN
Johnson & Johnson Is Exploring Bid for Intra-Cellular Therapies - MSN
Why Johnson & Johnson Is Buying Intra-Cellular Therapies In A $14.6 Billion Deal - Pulse 2.0
JPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bn - BioXconomy
J&J’s Top Rating at Risk Because of Intra-Cellular Deal - Bloomberg
Johnson & Johnson to acquire Intra-Cellular Therapies for $14.6bn - World Pharmaceutical Frontiers
Baird R W Downgrades Intra-Cellular Therapies (NASDAQ:ITCI) to Hold - MarketBeat
Leerink Partnrs Downgrades Intra-Cellular Therapies (NASDAQ:ITCI) to Hold - MarketBeat
Cantor Fitzgerald Upgrades Intra-Cellular Therapies (NASDAQ:ITCI) to Strong-Buy - MarketBeat
The Zacks Analyst Blog Highlights J&J, Eli Lilly, GSK And Intra-Cellular - Barchart
The Zacks Analyst Blog Highlights J&J, Eli Lilly, GSK and Intra-Cellular - Yahoo Finance
Johnson & Johnson acquires Intra-Cellular Therapies for $14.6 billion - European Biotechnology News
Piper Sandler Downgrades Intra-Cellular Therapies (ITCI) - MSN
JnJ to acquire Intra-Cellular Therapies for USD 14.6 billion - Medical Dialogues
J&J strikes $14.6 billion deal for Intra-Cellular Therapies - MSN
Johnson & Johnson's 'AAA' rating on Credit Watch Negative at S&P following Intra-Cellular Therapies acquisition - Investing.com
J&J Is in Talks to Buy $10 Billion Biotech Intra-Cellular - MSN
JNJ, GSK, LLY Announce M&A Deals at JP Morgan Conference - Yahoo Finance
Johnson & Johnson Bolsters Neuroscience Offerings with $14.6 Billion Acquisition of Intra-Cellular Therapies - Hoodline
Johnson & Johnson to Expand Neuroscience Portfolio with US$14.6 Billion Acquisition - Investing News Network
Intra-Cellular Therapies' (ITCI) Neutral Rating Reiterated at Piper Sandler - MarketBeat
J&J to leverage Intra-Cellular Therapies’ neurology portfolio - Yahoo Finance
Intra-Cellular Therapies (NASDAQ:ITCI) Sees Large Volume IncreaseTime to Buy? - MarketBeat
Johnson & Johnson acquires Intra-Cellular for $14.6bn - OutSourcing-Pharma.com
Cravath, Davis Polk advise on Johnson & Johnson’s $14.6bn Intra-Cellular acquisition - The Global Legal Post
Intra-Cellular Therapies stock jumps 34%: Can it ride the wave? - Dataconomy
ITCI Poised for Turnaround Amid Rising Mental Health Concerns - Yahoo Finance
J&J expands neuroscience capabilities with $14.6bn Intra-Cellular acquisition - PMLiVE
Intra Cellular Therapies Inc Azioni (ITCI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.35%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):